Table 3.
Secondary End Points
| Placebo: Total (n=294) Dx (n=187) PCI (n=107) | Verapamil: Total (n=297) Dx (n=191) PCI (n=106) | P Value | |
|---|---|---|---|
| RAS, % | 1.7 | 1.0 | 0.50 |
| Crossover due to RAS, % | 0.0 | 0.3 | 1.00 |
| Rate of code breaks, % | 3.4 | 1.3 | 0.11 |
| Overall verapamil use, % | 2.0 | 100 | <0.0001 |
| Procedural time (min), median (IQR) | 16.0 (9.0 to 30.0) | 17.0 (10.0 to 31.0) | 0.37 |
| Dx | 10.0 (8.0 to 15.8) | 11.0 (8.0 to 17.0) | 0.16 |
| PCI | 34.0 (25.0 to 50.8) | 36.0 (24.0 to 51.0) | 0.67 |
| Fluoroscopic time (min), median (IQR) | 4.4 (2.1 to 9.6) | 4.8 (2.4 to 10.7) | 0.28 |
| Dx | 2.5 (1.7 to 4.6) | 3.1 (1.8 to 4.8) | 0.20 |
| PCI | 11.4 (7.3 to 17.9) | 13.1 (7.4 to 18.4) | 0.48 |
| Contrast volume (mL), median (IQR) | 72.5 (48.0 to 146.0) | 75.0 (47.0 to 156.5) | 0.74 |
| Dx | 53.0 (41.0 to 70.8) | 53.0 (41.0 to 73.8) | 0.89 |
| PCI | 182.0 (117.0 to 252.3) | 179.5 (133.0 to 265.0) | 0.58 |
| Subjective pain (arbitrary, 1 to 6), % | 0.12 | ||
| 1 | 12.6 | 14.8 | |
| 2 | 54.8 | 56.2 | |
| 3 | 23.8 | 21.9 | |
| 4 | 5.1 | 5.7 | |
| 5 | 2.7 | 1.3 | |
| 6 | 1.0 | 0.0 | |
| Dx | 0.19 | ||
| 1 | 12.8 | 15.7 | |
| 2 | 55.1 | 53.4 | |
| 3 | 23.5 | 24.6 | |
| 4 | 3.2 | 5.2 | |
| 5 | 3.7 | 1.0 | |
| 6 | 1.6 | 0.0 | |
| PCI | 0.42 | ||
| 1 | 12.1 | 13.2 | |
| 2 | 54.2 | 61.3 | |
| 3 | 24.3 | 17.0 | |
| 4 | 8.4 | 6.6 | |
| 5 | 0.9 | 1.9 | |
| 6 | 0.0 | 0.0 | |
| Significant pain (arbitrary, ≥4), % | 8.8 | 7.1 | 0.45 |
| Dx | 8.6 | 6.3 | 0.44 |
| PCI | 9.3 | 8.5 | 1.00 |
Dx indicates diagnostic procedures (including fractional flow reserve [FFR] estimation without percutaneous coronary intervention [PCI]); RAS, radial artery spasm.